Role of formulation vehicles in taxane pharmacology

被引:260
作者
van Zuylen, L
Verweij, J
Sparreboom, A
机构
[1] Rotterdam Canc Inst, Daniel den Hoed Klin, Dept Med Oncol, NL-3008 AE Rotterdam, Netherlands
[2] Univ Rotterdam Hosp, Rotterdam, Netherlands
关键词
Cremophor EL; paclitaxel; Tween; 80; docetaxel; pharmacokinetics;
D O I
10.1023/A:1010618632738
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The non-ionic surfactants Cremophor EL (CrEL) and Tween 80, both used as formulation vehicles of many (anticancer) agents including paclitaxel and docetaxel, are not physiological inert compounds. We describe their biological properties, especially the toxic side effects, and their pharmacological properties, such as modulation of P-glycoprotein activity. In detail, we discuss their influence on the disposition of the solubilized drugs, with focus on CrEL and paclitaxel, and of concomitantly administered drugs. The ability of the surfactants to form micelles in aqueous solution as well as biological fluids (e.g. plasma) appears to be of great importance with respect to the pharmacokinetic behavior of the formulated drugs. Due to drug entrapment in the micelles, plasma concentrations and clearance of free drug change significant leading to alteration in pharmacodynamic characteristics. We conclude with some perspectives related to further investigation and development of alternative methods of administration.
引用
收藏
页码:125 / 141
页数:17
相关论文
共 153 条
  • [91] CLINICAL RELEVANCE OF P-GLYCOPROTEIN EXPRESSION IN HEMATOLOGICAL MALIGNANCIES
    NOOTER, K
    SONNEVELD, P
    [J]. LEUKEMIA RESEARCH, 1994, 18 (04) : 233 - 243
  • [92] CYTOTOXIC ACTIVITY OF TAXOL IN PRIMARY CULTURES OF TUMOR-CELLS FROM PATIENTS IS PARTLY MEDIATED BY CREMOPHOR EL
    NYGREN, P
    CSOKA, K
    JONSSON, B
    FRIDBORG, H
    BERGH, J
    HAGBERG, H
    GLIMELIUS, B
    BRODIN, O
    THOLANDER, B
    KREUGER, A
    LONNERHOLM, G
    JAKOBSSON, A
    OLSEN, L
    KRISTENSEN, J
    LARSSON, R
    [J]. BRITISH JOURNAL OF CANCER, 1995, 71 (03) : 478 - 481
  • [93] Ohtsu T, 1995, CLIN CANCER RES, V1, P599
  • [94] Onetto N, 1993, J Natl Cancer Inst Monogr, P131
  • [95] ONETTO N, 1995, PACLITAXEL CANC TREA, P21
  • [96] Quantitative determination of polysorbate 20 in nasal pharmaceutical preparations by high-performance liquid chromatography
    Oszi, Z
    Petho, G
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1998, 18 (4-5) : 715 - 720
  • [97] Panday VRN, 1997, CLIN DRUG INVEST, V14, P418
  • [98] PANDAY VRN, 1999, CLIN PHARM PACLITAXE, P109
  • [99] Podratz J.L., 1993, T AM SOC NEUROCHEM, V24, P229
  • [100] Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors
    Pronk, LC
    Schellens, JHM
    Planting, AST
    vandenBent, MJ
    Hilkens, PHE
    vanderBurg, MEL
    deBoerDennert, M
    Ma, J
    Blanc, C
    Harteveld, M
    Bruno, R
    Stoter, G
    Verweij, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) : 1071 - 1079